[This corrects the article DOI: 10.1371/journal.pone.0235637.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725392 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243960 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling.
Drugs R D
December 2024
Galapagos SASU, Romainville, France.
Background And Objective: This study provides a physiologically based pharmacokinetic (PBPK) model-based analysis of the potential drug-drug interaction (DDI) between cyclosporin A (CsA), a breast cancer resistance protein transporter (BCRP) inhibitor, and methotrexate (MTX), a putative BCRP substrate.
Methods: PBPK models for CsA and MTX were built using open-source tools and published data for both model building and for model verification and validation. The MTX and CsA PBPK models were evaluated for their application in simulating BCRP-related DDIs.
Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review.
Eye (Lond)
December 2024
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Proliferative Vitreoretinopathy (PVR) is a major complication of surgical repair for Rhegmatogenous Retinal Detachment (RRD). Methotrexate (MTX), a folate antimetabolite, has shown promise in targeting the pathological processes involved in PVR, such as cell proliferation inhibition, fibrosis and anti-inflammation. Systematic review examines the use of MTX in PVR by analysing different administration methods and outcomes.
View Article and Find Full Text PDFStage 1 Extensive Macular Atrophy with Pseudodrusen-Like Appearance Complicated by Multiple Evanescent White Dot Syndrome-Like Reaction.
Ocul Immunol Inflamm
December 2024
Harvard Retinal Imaging Lab, Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Purpose: To describe a case of early-stage Extensive Macular Atrophy with Pseudodrusen-like appearance (EMAP) presenting with acute monocular loss and atypical retinal lesions suggestive of posterior uveitis.
Methods: Case report with longitudinal follow-up including visual field testing and multimodal imaging.
Results: A 53-year-old woman presented with sudden vision loss in her right eye (RE).
Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial-24-week Outcomes of Uveitic Macular Edema Retreatment.
Ophthalmology
November 2024
Center for Clinical Trials and Evidence Synthesis, Departments of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Purpose: Evaluation of longer-term effectiveness of three intravitreal therapies (methotrexate, ranibizumab, or dexamethasone implant) for participants enrolled in the randomized comparative effectiveness trial the Macular Edema Ranibizumab versus Intravitreal anti-inflammatory Therapy (MERIT) Trial followed for24 weeks.
Design: Multicenter randomized controlled clinical trial with masked evaluation of retinal thickness and visual acuity.
Participants: Patients with persistent or recurrent uveitic macular edema.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!